Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Neuropsychopharmacology ; 44(6): 1177, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30787427

RESUMEN

The original version of this Article contained an error in the spelling of the author Anna K Radke, which was incorrectly given as Anna R Radke. This has now been corrected in both the PDF and HTML versions of the Article.

2.
Neuropsychopharmacology ; 44(6): 1163-1173, 2019 05.
Artículo en Inglés | MEDLINE | ID: mdl-30622300

RESUMEN

Obsessive-compulsive disorder (OCD) is a severe, chronic neuropsychiatric disorder with a strong genetic component. The SLC1A1 gene encoding the neuronal glutamate transporter EAAT3 has been proposed as a candidate gene for this disorder. Gene variants affecting SLC1A1 expression in human brain tissue have been associated with OCD. Several mouse models fully or partially lacking EAAT3 have shown no alterations in baseline anxiety-like or repetitive behaviors. We generated a transgenic mouse model (EAAT3glo) to achieve conditional, Cre-dependent EAAT3 overexpression and evaluated the overall impact of increased EAAT3 expression at behavioral and synaptic levels. Mice with EAAT3 overexpression driven by CaMKIIα-promoter (EAAT3glo/CMKII) displayed increased anxiety-like and repetitive behaviors that were both restored by chronic, but not acute, treatment with fluoxetine or clomipramine. EAAT3glo/CMKII mice also displayed greater spontaneous recovery of conditioned fear. Electrophysiological and biochemical analyses at corticostriatal synapses of EAAT3glo/CMKII mice revealed changes in NMDA receptor subunit composition and altered NMDA-dependent synaptic plasticity. By recapitulating relevant behavioral, neurophysiological, and psychopharmacological aspects, our results provide support for the glutamatergic hypothesis of OCD, particularly for the increased EAAT3 function, and provide a valuable animal model that may open novel therapeutic approaches to treat this devastating disorder.


Asunto(s)
Ansiedad/metabolismo , Conducta Animal/fisiología , Proteína Quinasa Tipo 2 Dependiente de Calcio Calmodulina/metabolismo , Corteza Cerebral/metabolismo , Transportador 3 de Aminoácidos Excitadores/metabolismo , Neostriado/metabolismo , Plasticidad Neuronal/fisiología , Trastorno Obsesivo Compulsivo/metabolismo , Animales , Línea Celular , Clomipramina/farmacología , Modelos Animales de Enfermedad , Transportador 3 de Aminoácidos Excitadores/genética , Fluoxetina/farmacología , Expresión Génica/genética , Ratones , Ratones Transgénicos , Neuroblastoma , Técnicas de Placa-Clamp , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...